1. Search Result
Search Result
Results for "

estrogen receptors

" in MedChemExpress (MCE) Product Catalog:

442

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

7

Peptides

56

Natural
Products

74

Isotope-Labeled Compounds

9

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13724

    ERA-923

    Estrogen Receptor/ERR Cancer
    Pipendoxifene is a selective estrogen receptor modulator (SERM).
    Pipendoxifene
  • HY-W654077

    BPAF-d4; 4,4'-(Perfluoropropane-2,2-diyl)diphenol-d4

    Estrogen Receptor/ERR Endocrinology
    Bisphenol AF-d4 is the isotope labelled analog of Bisphenol AF (HY-W013782). Bisphenol AF is a full agonist for the estrogen receptor. Bisphenol AF acts as an endocrine-disrupting chemical (EDC), activating estrogen through the estrogen receptor Era. Bisphenol AF-d4 can be used for the research of endocrinology and cancer .
    Bisphenol AF-d4
  • HY-144204

    Estrogen Receptor/ERR Endocrinology Cancer
    Estrogen receptor antagonist 5 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 5 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 165) .
    Estrogen receptor antagonist 5
  • HY-144206

    Estrogen Receptor/ERR Endocrinology
    Estrogen receptor antagonist 6 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 6 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 166) .
    Estrogen receptor antagonist 6
  • HY-144138

    Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 2 is a selective estrogen receptor downregulator. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 2 has the potential for the research of breast cancer diseases (extracted from patent WO2021228210A1, compound 3) .
    Estrogen receptor antagonist 2
  • HY-144137

    Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 1 is a selective estrogen receptor antagonist. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 1 has the potential for the research of breast cancer diseases (extracted from patent WO2021249533A1, compound 4) .
    Estrogen receptor antagonist 1
  • HY-172869

    Estrogen Receptor/ERR Cancer
    Estrogen receptor modulator 13 (Compound 5D) is an estrogen receptor antagonist. Estrogen receptor modulator 13 shows significant cytotoxicity against MCF7 cells with an IC50 value of 8.50 μM. Estrogen receptor modulator 13 is promising for research of breast cancers .
    Estrogen receptor modulator 13
  • HY-144139

    Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 3 is a potent antagonist of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. Estrogen receptor antagonist 3 has the potential for the research of cancer diseases (extracted from patent WO2021213358A1, compound 7) .
    Estrogen receptor antagonist 3
  • HY-144202

    Estrogen Receptor/ERR Cancer
    Estrogen receptor antagonist 4 is a potent antagonist of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. Estrogen receptor antagonist 4 has the potential for the research of cancer diseases (extracted from patent WO2021213358A1, compound 1) .
    Estrogen receptor antagonist 4
  • HY-172231

    Estrogen Receptor/ERR Cardiovascular Disease Cancer
    Hexolame is an estrogen receptors agonist with dual anticoagulant and estrogenic properties. Hexolame binds to estrogen receptors to induce anticoagulant effects by modulating clotting factors or platelet activity. Hexolame is promising for research of prostatic cancer and prevention of thrombosis .
    Hexolame
  • HY-151230

    Estrogen Receptor/ERR Cancer
    (-)-Erteberel is a selective estrogen receptor beta (ERβ) agonist. (-)-Erteberel can be utilized in the study of diseases mediated by estrogen receptor beta (ERβ), such as prostate cancer .
    (-)-Erteberel
  • HY-W040046

    Nafoxidene hydrochloride

    Estrogen Receptor/ERR Cancer
    Nafoxidine hydrochloride is a non-steroidal estrogen receptor antagonist with antitumor activity for breast cancer .
    Nafoxidine hydrochloride
  • HY-107045

    Estrogen Receptor/ERR Endocrinology
    CHF 4227 free base is an orally active and selective estrogen receptor modulator (SERM) with high affinity to the human estrogen receptor-α and -β (Ki values of 0.017 nM and 0.099 nM, respectively) .
    CHF 4227 free base
  • HY-135588

    Drug Metabolite Metabolic Disease
    Raloxifene 6,4'-Bis-β-D-glucuronide (compound IV) is a metabolite of Raloxifene. Raloxifene is a selective estrogen receptor antagonist for the prevention of osteoporosis .
    Raloxifene 6,4'-Bis-β-D-glucuronide
  • HY-122359B

    L-Centchroman fumarate; L-Ormeloxifene fumarate

    Estrogen Receptor/ERR Others
    Levormeloxifene (fumarate) is a stable salt form of Levormeloxifene. Levormeloxifene (fumarate) is an estrogen receptor modulator that plays an important role in prevention of postmenopausal bone loss .
    Levormeloxifene fumarate
  • HY-N9329

    Monoamine Oxidase Estrogen Receptor/ERR Metabolic Disease
    Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of monoamine oxidase (MAO), with an IC50 of 140 μM. Glicoricone binds to estrogen receptor (ER) and shows estrogen antagonist activity .
    Glicoricone
  • HY-79576

    Oestrone methyl ether; 3-O-Methylestrone

    Drug Intermediate Cancer
    Estrone 3-methyl ether (Oestrone methyl ether; 3-O-Methylestrone) is a synthetic intermediate useful for synthesis of estrogen receptor modulator .
    Estrone 3-methyl ether
  • HY-142926

    Estrogen Receptor/ERR Cancer
    ER degrader 2 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 2 has the potential for the research of cancer diseases (extracted from patent CN112830919A, compound 1) .
    ER degrader 2
  • HY-142925

    Estrogen Receptor/ERR Cancer
    ER degrader 1 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 1 has the potential for the research of cancer diseases (extracted from patent WO2021139756A1, compound 11) .
    ER degrader 1
  • HY-142927

    Estrogen Receptor/ERR Cancer
    ER degrader 3 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 3 has the potential for the research of cancer diseases (extracted from patent WO2018233591A1, compound 1) .
    ER degrader 3
  • HY-161692

    Estrogen Receptor/ERR Cancer
    ERα degrader 8 (Compound 18j) is a selective Estrogen Receptor degrader. ERα degrader 8 is degrader to MCF-7 cells with IC50 value of 0.15 μM .
    ERα degrader 8
  • HY-145341

    Estrogen Receptor/ERR Cancer
    GNE-149 is an orally bioavailable full antagonist of estrogen receptor α (ERα; IC50=0.053 nM). GNE-149 is a selective estrogen receptor degrader (SERD). GNE-149 can be used for the research of breast cancer .
    GNE-149
  • HY-P5464

    Estrogen Receptor/ERR Others
    SRC-1 NR box peptide is a biological active peptide (This peptide is a 14-amino acid fragment from the steroid receptor cofactor SRC-1 NR II). SRC-1 NR box peptide can be used to study the regulatory mechanisms of estrogen receptor ligands .
    SRC-1 NR box peptide
  • HY-W926789

    Estrogen Receptor/ERR Metabolic Disease Cancer
    (E)-GW7604 is the (E)-isomer of GW7604, an antiestrogen and a metabolite of GW5638 (HY-112746), which is a high-affinity estrogen receptor (ER) antagonist .
    (E)-GW7604
  • HY-143226

    Estrogen Receptor/ERR Metabolic Disease
    DK1 is a potent modulator of estrogen related receptor. DK1 has an ability in reducing blood glucose, and impacts the activity of ERRα receptor. DK1 has the potential for the research of diabetes .
    DK1
  • HY-160264

    PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ER Degrader-12 (Compound 70) is an estrogen receptor PROTAC degrader (DC50: <10 nM), and inhibits MCF-7 proliferation (DC50: <10 nM). PROTAC ER Degrader-12 has anticancer effect. Pink: ER ligand (HY-169978); Blue: E3 ligase ligand (HY-138793); Black: linker (HY-30756) .
    PROTAC ER Degrader-12
  • HY-132294

    Estrogen Receptor/ERR Cancer
    GNE-502 is an orally active and potent degrader for estrogen receptor (ER). GNE-502 can be used for the research of breast cancer .
    GNE-502
  • HY-138642
    Vepdegestrant
    3 Publications Verification

    ARV-471

    PROTACs Estrogen Receptor/ERR Cancer
    Vepdegestrant (ARV-471) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of about 2 nM .
    Vepdegestrant
  • HY-138642A

    (Rac)-ARV-471

    Estrogen Receptor/ERR PROTACs Cancer
    (Rac)-Vepdegestrant is the isomer of Vepdegestrant (HY-138642). Vepdegestrant ((R)-Lavandulol) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of about 2 nM .
    (Rac)-Vepdegestrant
  • HY-119418

    Estrogen Receptor/ERR Cancer
    Desketoraloxifene is an estrogen receptors alpha (ERα) activator at an AP-1 site. Desketoraloxifene can be used for the research of osteoporosis and breast cancer .
    Desketoraloxifene
  • HY-16950
    4-Hydroxytamoxifen
    25+ Cited Publications

    (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene

    Estrogen Receptor/ERR Cancer
    4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER .
    4-Hydroxytamoxifen
  • HY-133189

    PROTAC Linkers Endocrinology
    Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands . Bis-propargyl-PEG9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bis-propargyl-PEG9
  • HY-119437
    FLTX1
    2 Publications Verification

    Estrogen Receptor/ERR Cancer
    FLTX1 is a fluorescent Tamoxifen derivative that can specifically label intracellular Tamoxifen-binding sites (estrogen receptors) under permeabilized and non-permeabilized conditions. FLTX1 exhibits the potent antiestrogenic properties of Tamoxifen in breast cancer cells. FLTX1 is devoid of the estrogenic agonistic effect on the uterus .
    FLTX1
  • HY-16950R

    Estrogen Receptor/ERR Cancer
    4-Hydroxytamoxifen (Standard) is the analytical standard of 4-Hydroxytamoxifen. This product is intended for research and analytical applications. 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER .
    4-Hydroxytamoxifen (Standard)
  • HY-110157

    Estrogen Receptor/ERR Neurological Disease
    AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender selective neuroprotective effects in a male rat model of Parkinson's disease .
    AC-186
  • HY-112746

    DPC974; GW5638

    Estrogen Receptor/ERR Cancer
    Etacstil (GW5638) is a estrogen receptor antagonist that displays minimal uterotropic activity in ovariectomized rats and inhibits the agonist activity of Estradiol (HY-B0141), Tamoxifen (HY-13757A) and Raloxifene (HY-13738) in the environment. Etacstil is promising for research of breast cancer and bone protection .
    Etacstil
  • HY-168869

    PROTACs Estrogen Receptor/ERR Cancer
    Tamoxifen-PEG-Clozapine is an estrogen receptor α (ERα) PROTAC degrader. Tamoxifen-PEG-Clozapine degrades ERα via a ubiquitin-proteasome system that uses the ubiquitin protein ligase E3 component N-recognin 5. Tamoxifen-PEG-Clozapine can be used for the research of cancer . (Pink: ERα inhibitor (HY-W271653); Black: linker (HY-168870); Blue: CRBN Ligand (HY-G0021))
    Tamoxifen-PEG-Clozapine
  • HY-12452
    DPN
    10+ Cited Publications

    Diarylpropionitrile

    Estrogen Receptor/ERR Apoptosis Autophagy Neurological Disease
    DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor β (ERβ) selective ligand, with an EC50 of 0.85 nM. DPN has neuroprotective effects in a number of neurological diseases .
    DPN
  • HY-118861

    (E)-Clomiphene; trans-Clomiphene; Enclomifene

    Estrogen Receptor/ERR Metabolic Disease Endocrinology
    Enclomiphene ((E)-Clomiphene) is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes .
    Enclomiphene
  • HY-118861B

    (E)-Clomiphene hydrochloride; trans-Clomiphene hydrochloride; Enclomifene hydrochloride

    Estrogen Receptor/ERR Metabolic Disease Endocrinology
    Enclomiphene ((E)-Clomiphene) hydrochloride is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene hydrochloride can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes .
    Enclomiphene hydrochloride
  • HY-19822
    Elacestrant
    10+ Cited Publications

    RAD1901

    Estrogen Receptor/ERR Cancer
    Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
    Elacestrant
  • HY-19822A
    Elacestrant dihydrochloride
    10+ Cited Publications

    RAD1901 dihydrochloride

    Estrogen Receptor/ERR Cancer
    Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
    Elacestrant dihydrochloride
  • HY-101119

    Estrogen Receptor/ERR Cancer
    GLL398 is a potent, orally bioavailable selective estrogen receptor degrader (SERD) with an IC50 value of 1.14 nM. GLL398 shows a strong dose-dependent binding to ER with a mutation at Y537S (IC50=29.5 nM). GLL398 blocks tumor growth in xenograft models of breast cancer.
    GLL398
  • HY-118861A
    Enclomiphene citrate
    1 Publications Verification

    (E)-Clomiphene citrate; trans-Clomiphene citrate; Enclomifene citrate

    Estrogen Receptor/ERR Metabolic Disease Endocrinology
    Enclomiphene ((E)-Clomiphene) citrate is a potent and orally active non-steroidal estrogen receptor antagonist, with antioestrogenic property. Enclomiphene citrate can be used for the research of ovarian dysfunction, testosterone deficiency, male hypogonadism and type 2 diabetes .
    Enclomiphene citrate
  • HY-19822S2

    RAD1901-d10

    Estrogen Receptor/ERR Isotope-Labeled Compounds Cancer
    Elacestrant-d10 is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER + breast cancer cell lines in vitro and in vivo .
    Elacestrant-d10
  • HY-12452R

    Estrogen Receptor/ERR Apoptosis Autophagy Neurological Disease
    DPN (Standard) is the analytical standard of DPN. This product is intended for research and analytical applications. DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor β (ERβ) selective ligand, with an EC50 of 0.85 nM. DPN has neuroprotective effects in a number of neurological diseases .
    DPN (Standard)
  • HY-A0036
    Bazedoxifene acetate
    10+ Cited Publications

    TSE-424 acetate

    Estrogen Receptor/ERR Cancer
    Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
    Bazedoxifene acetate
  • HY-A0031
    Bazedoxifene
    10+ Cited Publications

    TSE-424

    Estrogen Receptor/ERR Cancer
    Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
    Bazedoxifene
  • HY-153478

    Estrogen Receptor/ERR Cancer
    Estrogen receptor modulator 7 is a potent estrogen receptor modulator. Estrogen receptor modulator 7 can be used in research of cancer .
    Estrogen receptor modulator 7
  • HY-A0031A

    TSE-424 hydrochloride

    Estrogen Receptor/ERR Cancer
    Bazedoxifene hydrochloride (TSE-424 hydrochloride) is an oral active, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene hydrochloride can be used for the research of osteoporosis. Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130 protein-protein interactions. Bazedoxifene hydrochloride can be used for the research of pancreatic cancer .
    Bazedoxifene hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: